The business of using artificial intelligence to find new drugs is starting to consolidate. The AI-powered drug discovery firm Recursion Pharmaceuticals will buy rival Exscientia in an all-stock deal ...
Salt Lake City USA, Oxford UK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) have each received overwhelming approval from their shareholders for the ...
For the first time ever, a demonstration version of one of Recursion's Compound Intelligence tools to explore maps of biology and chemistry is open for anyone to use RxRx3, the underlying dataset ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results